Psoriasis clinical trials at UCSF
4 in progress, 3 open to eligible people
Psoriasis is a skin condition that causes red, itchy patches. UCSF is studying how a drug called deucravacitinib affects immune cells in the skin and blood of people with psoriasis. Another study looks at how guselkumab affects psoriasis by blocking certain immune cell actions. UCSF is also researching the genetic response of psoriasis patients to guselkumab.
Correction of Psoriatic T Cell Signatures by Deucravacitinib
open to eligible people ages 18-75
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
San Francisco, California
Guselkumab Immunogenetics
open to eligible people ages 18 years and up
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
San Francisco, California
Immune Spatial Features of Guselkumab Cutaneous Response
open to eligible people ages 18 years and up
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
San Francisco, California
JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Fresno, California and other locations
Our lead scientists for Psoriasis research studies include Raymond Cho Wilson Liao, MD.
Last updated: